Yesterday, I wrote about how right-to-try and an unethical offshore vaccine trial are part of free market fundamentalists’ attack on the FDA. Here’s another example, the “right to choose medicine.”
Search: “"Stanislaw Burzynski"”
We found 388 results for your search.
So-called “right-to-try” is a cruel sham that holds out the mostly false hope of survival to terminally ill patients and their families. In return, all they have to give up is patient protections and agree to pay to be guinea pigs to test a drug company’s product. The product of an ideology that uses the terminally ill as shields to hide the ideological motives behind the law, which are to hobble the FDA, right-to-try is a terrible idea. It’s bad for patients, but it just passed the Senate and could well become the law of the land when the House reconvenes in September if it isn’t stopped.
Share this:
Many are the stories of those who have embraced quackery to treat their cancer. Few are followup stories when such a person realizes she’s made a mistake and returns to conventional therapy. This is one such story, but you’re unlikely ever to see the media outlets that touted Carissa Gleeson’s choice of quackery to treat her cancer run the story of her having changed her mind and saved her life with real medicine.
Share this:
I recently took a review course in general surgery to prepare for my board recertification examination in December and realized just how much the standard of care had changed in the decade since I last recertified. Then I learned that laetrile is still a thing. If there’s one thing that demonstrates the difference between alternative medicine and real medicine, it’s how no alternative medicine treatment ever goes away, no matter how often it’s shown not to work. Ever.
Share this:
“Right-to-try” laws claim to help terminally patients by allowing them access to experimental drugs before they are approved, when, in fact, their purpose is to undermine and weaken the FDA and such laws strip legal and regulatory protections from patients using such drugs. Now advocates are making a new push to pass right-to-try by embedding it in the very law that funds the FDA. They might succeed if they encounter no opposition from constituents.
